|
Post by lcd on Oct 9, 2017 12:33:01 GMT
I started following this one recently but haven't bought any yet. On Friday they purchased controlling interest in Tyrnovo, the oncology company that owns their oncology drug NT-219. It looks like they spent about $1.9 million for 27%, but what is really interesting is they did it with their own shares priced at $2.50. That doesn't seem like a very good deal for the Tyrnovo owners. I feel like the numbers are wrong somewhere in this transaction. What do you think? www.reuters.com/article/brief-kitov-boosts-ownership-in-tyrnovo/brief-kitov-boosts-ownership-in-tyrnovo-and-oncology-platform-idUSFWN1MH0CCThis company seems a little shady to me, or maybe it is just because I don't understand the ownership structure.
|
|
|
Post by JHam on Oct 11, 2017 16:31:34 GMT
Sudden spike in volume and this has taken off. Just hit $2.50 a few minutes ago. Wonder what's up.
|
|
|
Post by lcd on Oct 11, 2017 18:26:50 GMT
It was up over 50% on no news?! I hope people took some profits today.
|
|
|
Post by hansgruber on Oct 11, 2017 20:37:35 GMT
It was up over 50% on no news?! I hope people took some profits today. For once I'm glad i didn't. Wonder what leaked here. Weird.
|
|
|
Post by hansgruber on Oct 11, 2017 20:40:31 GMT
hit $3.50 after hours. Doesn't mean diddley necessarily but good to see regardless. Does shlomo/Bernstein know of any catalysts in near future? Last i saw nothing until next year with the fda application...
|
|
|
Post by hansgruber on Oct 11, 2017 20:42:41 GMT
Ok. Sorry. Just saw bernstein's post last page about kidney results this quarter. Maybe that's the cause of this bump?
|
|
|
Post by bernstein on Oct 11, 2017 21:01:43 GMT
It could be the Phase 3 results which could be released any day now or Partner deals for this drug below and Kit-302 which awaiting FDA approval "Based on the pre-clinical results generated to date, we are receiving solid preliminary interest from potential strategic partners for NT219, which presents a novel, first-in-class mechanism of action in the oncology field." finance.yahoo.com/news/kitov-boosts-ownership-tyrnovo-oncology-122000438.html
|
|
|
Post by lcd on Oct 11, 2017 21:06:08 GMT
I haven't done the DD on this stock and was questioning their ownership structure. I don't understand their relationship with Tyrnovo and I wonder if this company is similar to BrainStorm where there is a board member who is flushing cash into the company?
|
|
|
Post by JHam on Oct 12, 2017 2:07:10 GMT
Whoah, up 63% for the day (including AH) on 23x the daily volume!
This could be one of two things in my opinion. 1. Positive P3 Renal study data leaking out 2. Buyout
There have been rumors of a buyout for a while now. They are an easy target for big pharna; tiny company, only two drugs in the pipeline, and one late-stage potentially billion dollar drug.
At this time though, I think it is more likely 1. Renal study results are anticipated for this quarter after being pushed back from Q3. For those unfamiliar, NSAIDs, often times cause adverse effects such as heart disease and kidney failure. The data in 302 trials to this point have shown not only a positive trend in renal outcomes, but that the drug may have a positive renal benefit. They weren’t required to do a formal follow-study in order to file an NDA, but they did it anyway to a) Bolster the application and b) Because it would substantially increase the overall value of 302.
I’ll be surprised if we don’t see a PR in the AM tomorrow for the renal study.
|
|
|
Post by JHam on Oct 12, 2017 2:08:41 GMT
It was up over 50% on no news?! I hope people took some profits today. For once I'm glad i didn't. Wonder what leaked here. Weird. I didn’t either (not on purpose though, I was asleep). And per your other posts, I agree. This smells like it’s the renal study. Could be a buyout, but I doubt it.
|
|
|
Post by JHam on Oct 12, 2017 2:47:17 GMT
Incidentally, I am in no rush to sell this one at this point. They are almost at the finish line. In just a few months they could *should* receive NDA approval, and have a potential blockbuster drug (that shows 2.5x the efficacy of the current standard of care, plus possible improvement in renal function) on the market. If this were currently in P2 or P3 then I would be looking to sell my position tomorrow. That said, if this goes crazy tomorrow on no news, then I may sell some trading shares.
I have a medium position and am currently up exactly 100%. Should have bought more, but I guess that’s how it goes. Gotta love these low float biotechs! Good luck to all of us!
|
|
|
Post by JHam on Oct 12, 2017 10:10:37 GMT
Whoah, up 63% for the day (including AH) on 23x the daily volume! This could be one of two things in my opinion. 1. Positive P3 Renal study data leaking out 2. Buyout There have been rumors of a buyout for a while now. They are an easy target for big pharna; tiny company, only two drugs in the pipeline, and one late-stage potentially billion dollar drug. At this time though, I think it is more likely 1. Renal study results are anticipated for this quarter after being pushed back from Q3. For those unfamiliar, NSAIDs, often times cause adverse effects such as heart disease and kidney failure. The data in 302 trials to this point have shown not only a positive trend in renal outcomes, but that the drug may have a positive renal benefit. They weren’t required to do a formal follow-study in order to file an NDA, but they did it anyway to a) Bolster the application and b) Because it would substantially increase the overall value of 302. I’ll be surprised if we don’t see a PR in the AM tomorrow for the renal study. One more possibility I should have added to my list here was 3. Partneship. KTOV has been discussing how they are in advanced partnership discussions in both the US and Europe.
|
|
|
Post by JHam on Oct 13, 2017 13:59:45 GMT
Looks like there is no PR I still think something positive probably leaked. They just haven’t reported it yet.
|
|
|
Post by lcd on Jan 31, 2018 17:58:59 GMT
I took a small position in KTOV late last fall for a runup to FDA review in May and it appears that other investors might be starting to get in too. The fact that it spiked to almost $3.50 last fall gives me some confidence there will be a nice runup over $4 before the May 31 completion date.
I still have some unanswered questions about the ownership structure of this company, and there is still an ongoing fraud investigation regarding the company's interactions with the Data Monitoring Committee during the KIT-302 trial so I don't expect to hold this one through the end of May, nor do I plan to add to my current holdings at this point.
|
|
|
Post by lcd on Apr 12, 2018 15:15:24 GMT
With just over a month until FDA review I am surprised to see this stock so flat. There was a conversation on Twitter where someone suggested they missed filing documents on additional tests so the review will be delayed 90 days. I don't know how valid this is but I expected to see the price at least over the $3.50 mark it hit for no reason last fall. That spike is the reason I invested in this company because I assume the pps would go higher than that again before the end of May. Anyone else still holding?
|
|
|
Post by JHam on Apr 16, 2018 15:36:33 GMT
With just over a month until FDA review I am surprised to see this stock so flat. There was a conversation on Twitter where someone suggested they missed filing documents on additional tests so the review will be delayed 90 days. I don't know how valid this is but I expected to see the price at least over the $3.50 mark it hit for no reason last fall. That spike is the reason I invested in this company because I assume the pps would go higher than that again before the end of May. Anyone else still holding? I am out of this one at the moment, but it is still on my watch list. Actually I have been out of the game for a bit now (had some things to take care of), although I maintained a 50% position in RDHL. Chomping at the bit to re-open some positions in a few stocks, and this is one of them. Not sure why this one is trading the way it is, but I do imagine a run-up is in the works as we get closer to the FDA review.
|
|
|
Post by lcd on May 31, 2018 17:57:00 GMT
Consensi was approved by the FDA today. The stock is halted and the price is still far below the run up to the mid-3's last fall so I don't know what to expect once trading resumes, but I am getting out sometime in the next few trading periods. I never got into this one as a long term investment.
|
|
|
Post by JHam on May 31, 2018 22:20:58 GMT
Consensi was approved by the FDA today. The stock is halted and the price is still far below the run up to the mid-3's last fall so I don't know what to expect once trading resumes, but I am getting out sometime in the next few trading periods. I never got into this one as a long term investment. I saw this. Ran up to $3.81. Did you get out? Either way, congrats!
|
|
|
Post by lcd on May 31, 2018 22:48:40 GMT
Thanks. I had a meeting when trading resumed and it was already back down near $3 by the time I was done so I am still holding. I thought it would go over $4 today which was my target sale price. I think KTOV will get $3 million from their Chinese partner for approval and are already in good shape financially so I am hopeful the price will rise back towards $4 tomorrow when the Israeli market is open. Alternatively, I could wait for American partnership news but I have already held this one much longer then anticipated.
|
|
|
Post by JHam on Jun 1, 2018 5:33:46 GMT
Thanks. I had a meeting when trading resumed and it was already back down near $3 by the time I was done so I am still holding. I thought it would go over $4 today which was my target sale price. I think KTOV will get $3 million from their Chinese partner for approval and are already in good shape financially so I am hopeful the price will rise back towards $4 tomorrow when the Israeli market is open. Alternatively, I could wait for American partnership news but I have already held this one much longer then anticipated.Yeah that is what I was thinking. It's good news that they received approval and *surely* means (cause I'm never wrong) that they will look to partner up. You never know though and that could take some time so probably not a bad idea to cut and run with a profit when you can. Good luck!
|
|